Impact of Clinical Pharmacist Interventions in Vitamin K Antagonists Management at One Teaching Hospital in Vietnam

Author(s):  
2013 ◽  
Vol 16 (7) ◽  
pp. A467
Author(s):  
J. Gallagher ◽  
S. Mc Carthy ◽  
D. Lynch ◽  
N. Woods ◽  
S. Byrne

2013 ◽  
Vol 11 (2) ◽  
pp. 190-196 ◽  
Author(s):  
Wálleri Christini Torelli Reis ◽  
Carolinne Thays Scopel ◽  
Cassyano Januário Correr ◽  
Vânia Mari Salvi Andrzejevski

OBJECTIVE: To analyze the clinical pharmacist interventions performed during the review of prescription orders of the Adult Intensive Care, Cardiologic Intensive Care, and Clinical Cardiology Units of a large tertiary teaching hospital in Brazil. METHODS: The analysis took place daily with the following parameters: dose, rate of administration, presentation and/or dosage form, presence of inappropriate/unnecessary drugs, necessity of additional medication, more proper alternative therapies, presence of relevant drug interactions, inconsistencies in prescription orders, physical-chemical incompatibilities/solution stability. From this evaluation, the drug therapy problems were classified, as well as the resulting clinical interventions. RESULTS: During the study, a total of 6,438 drug orders were assessed and 933 interventions were performed. The most prevalent drug therapy problems involved ranitidine (28.44%), enoxaparin (13.76%), and meropenem (8.26%). The acceptability of the interventions was 76.32%. The most common problem found was related to dose, representing 46.73% of the total. CONCLUSION: Our study showed that up to 14.6% of the prescriptions reviewed had some drug therapy problem and the pharmacist interventions have promoted positive changes in seven to ten of these prescriptions.


PLoS ONE ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. e0210779 ◽  
Author(s):  
João Paulo Vilela Rodrigues ◽  
Fabiana Angelo Marques ◽  
Ana Maria Rosa Freato Gonçalves ◽  
Marília Silveira de Almeida Campos ◽  
Tiago Marques dos Reis ◽  
...  

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
James Gallagher ◽  
Stephen Byrne ◽  
Noel Woods ◽  
Deirdre Lynch ◽  
Suzanne McCarthy

2006 ◽  
Vol 26 (01) ◽  
pp. 52-54 ◽  
Author(s):  
P. A. Kyrle

SummaryVenous thrombosis is a chronic disease with a recurrence rate of approximately 30% within 5-8 years. The optimal duration of secondary thromboprophylaxis in these patients entails balancing the risk of recurrence against the risk of treatment-associated bleeding. There is agreement that patients with a first idiopathic venous thrombosis should receive vitamin K antagonists for at least 3-6 months. Convincing trials showing a clinical benefit in terms of morbidity or mortality with respect to expansion of anticoagulation beyond 6 months are lacking. Nevertheless, some subgroups of patients with venous thrombosis may benefit from indefinite anticoagulation. Thus, patients with antithrombin deficiency, combined or homozygous defects, more than one unprovoked episode of thrombosis, the lupus anticoagulant or high factor VIII plasma levels are good candidates for long-term prevention.


Sign in / Sign up

Export Citation Format

Share Document